Interwell Health, a national leader in value-based kidney care and a division of Fresenius Medical Care, has appointed Carney Taylor, MD, MBA, as its new chief medical officer. Dr. Taylor will lead clinical strategy, physician engagement, and quality initiatives, succeeding Dr. George Hart, who retired as CMO on January 1 but will continue to support the organization in a strategic advisory capacity to ensure a smooth transition.
Health Technology Insights: AHN Offers Innovative Low-Dose Radiation Therapy for Osteoarthritis
Tommy O’Connor, CEO of Interwell Health, praised Dr. Taylor as an outstanding care provider with decades of experience supporting patients throughout their healthcare journeys. O’Connor highlighted Dr. Taylor’s collaborative leadership style, noting that he ensures the perspectives of Interwell’s 2,300 network nephrologists are central to shaping the organization’s clinical strategy for the future.
Dr. Taylor brings more than twenty-five years of experience in nephrology and practice management and is recognized as a pioneer in value-based kidney care. He has previously held multiple leadership roles within Interwell, including associate chief medical officer and board member. Before joining Interwell, Dr. Taylor served as co-president of Eastern Nephrology Associates in North Carolina, one of the first practices to partner with Interwell and a leading participant in the federal value-based kidney care program.
Health Technology Insights: CareTrust Acquires $142 Million Mid-Atlantic Nursing Portfolio
In his new role, Dr. Taylor emphasized the effectiveness of Interwell’s physician-led model. He stated that the organization’s engaged clinician network, nephrology-focused electronic health record, and coordinated care approach enable better patient outcomes, help payers manage costs, and allow physicians to focus on the aspects of medicine that bring them professional satisfaction.
As value-based kidney care programs continue to grow nationwide, there is increasing demand for approaches that are both clinically effective and economically sustainable. Dr. Taylor’s appointment ensures that Interwell Health maintains its standard of clinical excellence while expanding its innovative programs to serve more patients living with kidney disease under the guidance of CEO Tommy O’Connor.
Health Technology Insights: Natera Launches 21-Gene Fetal Focus Single-Gene NIPT
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
